NIR-responsive Cu2 − xSe@Fc nanoparticles for photothermal- ferroptosis combination therapy in esophageal cancer
Esophageal cancer (EC) represents a highly recurrent and aggressive malignancy within the digestive system. However, conventional therapeutic strategies exhibit notable limitations in their clinical applications. Photothermal therapy (PTT), combined with ferroptosis, has attracted considerable attentions, emerging as a promising novel strategy for EC treatment. Therefore, there is a critical need to develop a drug delivery system capable of effectively integrating these two therapeutic approaches. In this work, we report a novel drug delivery system based on ferrocene (Fc), which is mixed with lauric acid (a phase-change material with a melting point around 44 <sup>o</sup>C) and then coated on the surface of Cu<sub>2 - x</sub>Se nanoparticles. The photothermal properties of Cu<sub>2 - x</sub>Se triggers the melting of lauric acid under near-infrared (NIR) laser irradiation, facilitating controlled release of Fc. Following internalization by tumor cells via endocytosis, the synergistic effect of PTT and ferroptosis, triggered by Cu<sub>2 - x</sub>Se@Fc, induced immunogenic cell death, which promoted dendritic cell maturation and cytotoxic T lymphocytes recruitment while decreasing the proportion of regulatory T cells, thereby strengthening the antitumor immune surveillance and improving the therapeutic efficacy of Anti-PD-1 blockade. These findings propose that the NIR-responsive Cu<sub>2 - x</sub>Se@Fc formulation represents a promising and effective strategy with prospecting application for cancer treatment.
Authors
- Linlin Shi (ORCID: https://orcid.org/0000-0001-9089-2388)
- Zhifeng Qu (ORCID: https://orcid.org/0009-0001-6520-6363)
- Fengqi Zhang (ORCID: https://orcid.org/0000-0002-4091-2464)
- Shegan Gao (ORCID: https://orcid.org/0000-0001-9055-1479)
- Jiayi Li (ORCID: https://orcid.org/0000-0002-8041-8049)
- Ying Yu (ORCID: https://orcid.org/0000-0002-7680-7180)
- Haoyan Cheng (ORCID: https://orcid.org/0000-0002-6328-1546)
- Peng Yang (ORCID: https://orcid.org/0000-0002-2746-744X)
- Ke Liu (ORCID: https://orcid.org/0000-0002-2652-1774)
- Xiaoman Zhang (ORCID: https://orcid.org/0000-0003-3428-1640)
- Chen Pan (ORCID: https://orcid.org/0000-0003-1554-541X)
- Beng Ma
Institutions
- First Affiliated Hospital of Henan University of Science and Technology (CN)
- Henan Cancer Hospital (CN)
Publication Details
- Journal
- Journal of Nanobiotechnology
- Published
- 2025-05-16
- DOI
- https://doi.org/10.1186/s12951-025-03434-7
- Citations
- 4
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 2.70
Funders
- National Natural Science Foundation of China